Nak Seila, born in 1992 in a small farming village in Tbong Khmum province, about 140 km from Phnom Penh, faced a challenging childhood due to repeated bleeding episodes. From the age of five, he experienced frequent acute bleeds and relied on hospital visits for fresh frozen plasma infusions. His education was disrupted, and he left school in grade 5. On-demand treatment over the years could not prevent permanent damage to some of his joints, including limited mobility in his left knee.
In late 2019, Seila was referred to a hemophilia treatment centre in Phnom Penh, where he was diagnosed with moderate hemophilia A and began receiving factor provided by the WFH Humanitarian Aid Program. Because of his physically demanding job as a mechanic, physicians later put him on a monthly prophylactic non-factor replacement therapy program. This treatment—which he can self-administer at home through injections—has kept him free from bleeding episodes, greatly improving his mobility and independence.
I am very happy to be on this treatment program which, allows me to work as a mechanic. I would like to express my gratitude to the WFH and the WFH Humanitarian Aid Program.
—Nak Seila, person with hemophilia from Cambodia
The WFH Humanitarian Aid Program has donated over 19 million IUs of factor and over 470,000 mg of non-factor replacement therapy to Cambodia since 2015. Over 3.7 million IUs of factor, and over 140,000 mg of non-factor replacement therapy were donated in 2024 alone. To find out more about the WFH Humanitarian Aid Program, please click here.
About the WFH Humanitarian Aid Program
The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care. None of this would be possible without the generous support of Sanofi and Sobi, our Founding Visionary Contributors; Bayer, CSL Behring and Roche, our Visionary Contributors; Grifols, our Leadership Contributor; and Takeda, our Contributor. To learn more about the WFH Humanitarian Aid Program, visit www.treatmentforall.org.
